• 1
    Curran WJJr,Scott CB,Horton J, et al. Recursive partitioning analysis of prognostic factors in 3 Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993; 85: 704-710.
  • 2
    Stupp R,Mason WP,van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996.
  • 3
    Stupp R,Gander M,Leyvraz S,Newlands E. Current and future developments in the use of temozolomide for the treatment of brain tumours brain tumours. Lancet Oncol. 2001; 2: 552-560.
  • 4
    Omuro AM,Delattre JY. What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas? Curr Opin Neurol. 2008; 21: 717-719.
  • 5
    Zuniga RM,Torcuator R,Jain R, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol. 2009; 91: 329-336.
  • 6
    Chang SM,Wen P,Cloughesy T, et al. North American Brain Tumor Consortium and the National Cancer Institute. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005; 23: 357-361.
  • 7
    Reardon DA,Desjardins A,Vredenburgh JJ, et al. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. Neuro Oncol. 2008; 10: 330-340.
  • 8
    Schlitzer M. Malaria chemotherapeutics, part I: history of antimalarial drug development, currently used therapeutics, and drugs in clinical development. Chem Med Chem. 2007; 2: 944-986.
  • 9
    Finesilver AG. Newer approaches to the treatment of rheumatoid arthritis. WMJ. 2003; 102: 34-37.
  • 10
    Toler SM,Noe D,Sharma A. Selective enhancement of cellular oxidative stress by chloroquine: implications for the treatment of glioblastoma multiforme. Neurosurg Focus. 2006; 21: 10-14.
  • 11
    Reyes S,Herrera LA,Ostrosky P, et al. Quinacrine enhances carmustine therapy of experimental rat glioma. Neurosurgery. 2001; 49: 969-973.
  • 12
    Michael RO,Williams GM. Chloroquine inhibition of repair of DNA damage induced in mammalian cells by methyl methanesulfonate. Mutat Res. 1974; 25: 391-396.
  • 13
    Savarino A,Boelaert JR,Cassone A, et al. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis. 2003; 3: 722-727.
  • 14
    Zhao H,Cai Y,Santi S, et al. Chloroquine-mediated radiosensitization is due to the destabilization of the lysosomal membrane and subsequent induction of cell death by necrosis. Radiat Res. 2005; 164: 250-257.
  • 15
    Sotelo J,Briceno E,Lopez-Gonzalez MA. Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2006; 144: 337-343.
  • 16
    Briceno E,Calderon A,Sotelo J. Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme. Surg Neurol. 2007; 67: 388-391.
  • 17
    van Halm VP,Nurmohamed MT,Twisk JW,Dijkmans BA,Voskuyl AE. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study [serial onnline]. Arthritis Res Ther. 2006; 8: R151.